Medtronic plc reports strong third quarter results for fiscal 2026, marking its highest enterprise revenue growth in 10 quarters.
Q3 revenue reaches $9.0 billion, up 8.7% reported and 6.0% organic. GAAP diluted EPS is $0.89 and non GAAP diluted EPS is $1.36. The company reiterates its full year organic revenue growth guidance of about 5.5% and non GAAP EPS guidance of $5.62 to $5.66.
The Cardiovascular portfolio grows 11% year over year, with Cardiac Ablation Solutions rising 80% driven by pulsed field ablation products. The company secures CE Mark for Sphere 360, U.S. FDA clearance for the Hugo robotic assisted surgery system and clearance for the Stealth AXiS Surgical System.
By segment, Cardiovascular revenue totals $3.46 billion, Neuroscience $2.56 billion, Medical Surgical $2.17 billion and Diabetes $796 million, with Diabetes growing 8.3% organically.
Operating profit is $1.46 billion on a GAAP basis. Medtronic also completes acquisitions of CathWorks and Anteris to support its growth strategy.
Leave a comment